Views & Analysis Unstable and unpredictable? The reality of the PPRS Has the UK PPRS scheme met its five objectives?
Views & Analysis Just how much does the NHS spend on medicines? Confidential discounts and the PPRS pricing system are making it more difficult to arrive at an accurate figure.
Views & Analysis Three NICE thresholds for cost-effectiveness: does that make... NICE wants a new, third threshold for rare disease drugs - but what's the evidence behind it?
Views & Analysis The PPRS medicines pricing scheme: is it working for both si... The PPRS has now reached the half-way stage - a look at the stats so far.
Views & Analysis International benchmarking and NICE Is NICE willing to change, or is it inflexible? It is being pressed to compare itself to other HTA organisations.
Views & Analysis Sitting uncomfortably? The UK’s PPRS and statutory schemes Do the PPRS and the statutory scheme run effectively in parallel?
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
